I truly believe many would be happy to use it. I checked with my doctor about using it and I got a prescription. I am tired of being stabbed and be burden with a needle shot on my next medication. I will be at ease and I will have a better quality of life with my improved (inhaled) insulin medication.
In June 2014, La Jolla had a meeting with the U.S. Food and Drug Administration, or FDA, in which agreement was reached that blood pressure can be the primary endpoint for approval in CRH. As a result of this meeting, La Jolla plans to initiate a Phase 3 registration clinical trial of LJPC-501 in CRH in the first quarter of 2015. La Jolla believes CRH to be an orphan indication, and, therefore, in July 2014, La Jolla submitted an Orphan Drug Designation application to the FDA for LJPC-501 in the treatment of CRH.
When the fast track news came hypers were ecstatic, today hypers are doing the noisy chatter ...... the secondary offering was calming them down only because they did not get the price of the offering. They better just sit tight now because the offering price is way down. I can not say how low but I suggest sell and keep the gain.
My guess is an amazing earnings report. I have read most new orders on Tasers and cameras ..... it is all outstanding.
to control the market price artificially high ! Obviously, to declare a $20 -$24 offering price will be bad. But anyone to argue it is high price offering is a dummy, because it has not made the market price any higher except to go down.
my source is showing a strong sentiment on $20 - $22. It will be a hard hit at $20 but very nice when the brokers have the right to buy more or less 15% of the offering at the market.